Biotech News
Related news
TSHATaysha Gene Therapies2026-08-03 12:00 EST
Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
OCGNOcugen2026-07-13 11:02 EST
Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
MXCTMaxCyte2026-09-23 12:05 EST
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
MXCTMaxCyte2026-06-23 13:00 EST
VectorBuilder Partners with MaxCyte® to Advance Clinical-Grade Cell Engineering
SNYSanofi2026-09-14 13:03 EST
Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines
SNYSanofi2026-10-01 05:00 EST
Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
CRBUCaribou2026-06-29 12:00 EST
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
NTLAIntellia2026-09-08 12:00 EST
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
RHHBYRoche Holdings AG2026-08-20 15:45 EST
Roche’s US subsidiary Genentech announces manufacturing expansion in the United States
ABEOAbeona Therapeutics2026-08-04 11:30 EST
CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®
MaxCyte
Cell Engineering Platform MaxCyte provides electroporation systems and services used to engineer cells for research, clinical development, and commercial cell therapies. ExPERT Platform The ExPERT instrument family uses Flow Electroporation technology to introduce molecules into diverse cell types from laboratory through commercial scale...
Recent company news
MXCTMaxCyte2026-09-23 12:05 EST
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
MXCTMaxCyte2026-09-11 20:30 EST
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MXCTMaxCyte2026-08-19 12:05 EST
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
MXCTMaxCyte2026-08-12 20:05 EST
MaxCyte Reports Second Quarter 2026 Financial Results
MXCTMaxCyte2026-07-21 12:05 EST
MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development
Stock data
- Close
- 1.09 USD
- Market cap
- 131.76M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States